Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:MACK

Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis

Merrimack Pharmaceuticals logo

About Merrimack Pharmaceuticals Stock (NASDAQ:MACK)

Key Stats

Today's Range
$15.13
$15.13
50-Day Range
$14.65
$15.13
52-Week Range
$11.53
$15.89
Volume
N/A
Average Volume
396,929 shs
Market Capitalization
$223.77 million
P/E Ratio
1.09
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Stock News Headlines

Wall Street Icon: “You must get on the right side of this thing”
I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.
See More Headlines

MACK Stock Analysis - Frequently Asked Questions

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced its quarterly earnings results on Friday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.14.

Shares of Merrimack Pharmaceuticals reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Merrimack Pharmaceuticals investors own include Rite Aid (RAD), Agenus (AGEN), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Bristol-Myers Squibb (BMY) and Meta Platforms (META).

Company Calendar

Last Earnings
5/10/2019
Today
12/16/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MACK
Previous Symbol
NASDAQ:MACK
CUSIP
59032810
Employees
426
Year Founded
2000

Profitability

Net Income
$-1,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.31 per share

Miscellaneous

Free Float
10,267,000
Market Cap
$223.77 million
Optionable
Optionable
Beta
1.45

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

This page (NASDAQ:MACK) was last updated on 12/16/2024 by MarketBeat.com Staff
From Our Partners